Market Place
Sourcing Support
GENFIT Announces Updates & Participation at Liver Meeting® 2024
13 Nov 2024 //
GLOBENEWSWIRE
GENFIT Reports Q3 2024 Financial Information
07 Nov 2024 //
GLOBENEWSWIRE
Genfit moves to jump-start enrollment in liver failure trial
21 Sep 2024 //
FIERCE BIOTECH
GENFIT Reports First Half-Year 2024 Financial Results
19 Sep 2024 //
GLOBENEWSWIRE
EMA Committee Gives Positive Opinion On Ipsen`s Iqirvo For PBC
26 Jul 2024 //
GLOBENEWSWIRE
GENFIT Reports Half-Year Liquidity Contract With Credit Industriel
09 Jul 2024 //
GLOBENEWSWIRE
GENFIT: New Guidelines Include NIS2+® As Key Tool For Detecting At-Risk MASH
17 Jun 2024 //
GLOBENEWSWIRE
US FDA grants accelerated approval to Genfit and Ipsen`s liver disease drug
11 Jun 2024 //
REUTERS
GENFIT Highlights Ipsen`s Iqirvo Accelerated FDA Approval For Cholangitis
10 Jun 2024 //
GLOBENEWSWIRE
GENFIT to Present Latest ACLF Research at EASL Congress„ 2024
29 May 2024 //
GLOBENEWSWIRE
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
22 May 2024 //
GLOBENEWSWIRE
GENFIT Reports First Quarter 2024 Financial Information
14 May 2024 //
GLOBENEWSWIRE
GENFIT Publishes 2024 Extra-Financial Performance Report
25 Apr 2024 //
GLOBENEWSWIRE
GENFIT 2024 AGM Preparatory Documents Available
15 Apr 2024 //
GLOBENEWSWIRE
GENFIT Announces Publication of the 2023 Universal Reg Doc & the 2023 AR
05 Apr 2024 //
GLOBENEWSWIRE
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
04 Apr 2024 //
GLOBENEWSWIRE
GENFIT Announces 2024 Financial Calendar
15 Jan 2024 //
GLOBENEWSWIRE
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in PBC
08 Dec 2023 //
GLOBENEWSWIRE
GENFIT Announces Publication on the Accurate Performance of NIS2+
06 Dec 2023 //
GLOBENEWSWIRE
GENFIT Highlights ACLF Development Strategy at ACLF Day during AASLD
16 Nov 2023 //
GLOBENEWSWIRE
Results from Ipsen™s ELATIVE Phase III trial of elafibranor in PBC presented
13 Nov 2023 //
GLOBENEWSWIRE
GENFIT to Present Update on Corporate Progress at The Liver Meeting® 2023
02 Nov 2023 //
GLOBENEWSWIRE
GENFIT Announces Publication Confirming the Performance of its NASH Technology
26 Sep 2023 //
GLOBENEWSWIRE
GENFIT Reports First Half-Year 2023 Financial Results
20 Sep 2023 //
GLOBENEWSWIRE
GENFIT to Participate in Upcoming Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
GENFIT Announces the Publication of New Data on Clinical Performance of NIS2+
10 Aug 2023 //
GLOBENEWSWIRE
Celloram Inc. Strikes Landmark Licensing Deal with French Biotech GENFIT
31 Jul 2023 //
PR NEWSWIRE
Ipsen, Genfit`s elafibranor hits main goal of primary biliary cholangitis study
01 Jul 2023 //
PRESS RELEASE
Ipsen & GENFIT Announce +ve Results from Ph III ELATIVE® trial of elafibranor
30 Jun 2023 //
GLOBENEWSWIRE
GENFIT Announces Data at European Association for the EASL Congress 2023
07 Jun 2023 //
GLOBENEWSWIRE
Genfit licenses liver failure drug from Seal Rock in $107M deal
01 Jun 2023 //
FIERCE BIOTECH
GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset
31 May 2023 //
GLOBENEWSWIRE
GENFIT: May 24, 2023 Combined Shareholders Meeting results
24 May 2023 //
GLOBENEWSWIRE
GENFIT Announces Publication of the Development & Validation of NIS2+
23 May 2023 //
GLOBENEWSWIRE
GENFIT Reports First Quarter 2023 Financial Information
11 May 2023 //
GLOBENEWSWIRE
GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week
09 May 2023 //
GLOBENEWSWIRE
GENFIT Announces Publication of Extra-Financial Performance Report 2022
27 Apr 2023 //
GLOBENEWSWIRE
GENFIT Annual Combined General Meeting of May 24, 2023 Availability
19 Apr 2023 //
GLOBENEWSWIRE
GENFIT Announces Publication of the 2022 Universal Registration & the 2022
18 Apr 2023 //
GLOBENEWSWIRE
Genfit Reports Full-Year 2022 Financial Results and Provides Corporate Update
13 Apr 2023 //
GLOBENEWSWIRE
GENFIT Announces Revenues and Cash Position as of December 31, 2022
28 Feb 2023 //
GLOBENEWSWIRE
GENFIT Announces 2023 Financial Calendar
24 Jan 2023 //
GLOBENEWSWIRE
GENFIT to Participate in Upcoming Investor Conferences
05 Jan 2023 //
GLOBENEWSWIRE
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Liver Diseases
17 Nov 2022 //
GLOBENEWSWIRE
GENFIT Announces Compelling Results for Non-Invasive Diagnostic Technology NIS2+
25 Oct 2022 //
GLOBENEWSWIRE
GENFIT Announces Signature of the Share Purchase Agreement tis
29 Sep 2022 //
GLOBENEWSWIRE
Genfit revs up liver failure strategy with $41M biotech buyout
19 Sep 2022 //
FIERCEBIOTECH
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis
19 Sep 2022 //
GLOBENEWSWIRE
FDA Grants GENFIT’s GNS561 Orphan Drug Designation for Cholangiocarcinoma
13 Sep 2022 //
GLOBENEWSWIRE
GENFIT: Half-Year Report of Liquidity Contract with Credit
08 Jul 2022 //
GLOBENEWSWIRE
GENFIT: May 25, 2022 Combined Shareholders Meeting results
25 May 2022 //
GLOBENEWSWIRE
GENFIT Reports First Quarter 2022 Financial Information
11 May 2022 //
GLOBENEWSWIRE
GENFIT Announces Publication of the 2021 Universal Registration Document
29 Apr 2022 //
GLOBENEWSWIRE
GENFIT Annual Combined General Meeting of May 25, 2022
20 Apr 2022 //
GLOBENEWSWIRE
Genfit bounces back from omicron to keep phase 3 trial on track
09 Apr 2022 //
FIERCEBIOTECH
GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update
07 Apr 2022 //
GLOBENEWSWIRE
GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021
28 Feb 2022 //
GLOBENEWSWIRE
Ipsen ends 2021 deal spree with $543M Genfit tie-up
18 Dec 2021 //
FIERCEBIOTECH
Ipsen places €480m bet on Genfit’s liver drug elafibranor
17 Dec 2021 //
PHARMAPHORUM
On heels of global strategic partnership announced today, GENFIT acquires rights
17 Dec 2021 //
GLOBENEWSWIRE
